Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

被引：7

作者：

Costanzo, Antonio ^{[1
,2
]}

Russo, Filomena ^{[3
]}

Galluzzo, Marco ^{[4
,5
]}

Stingeni, Luca ^{[6
,7
]}

Scuderi, Roberta ^{[8
]}

Zichichi, Leonardo ^{[9
]}

Papini, Manuela ^{[10
]}

Di Costanzo, Luisa ^{[11
]}

Conti, Andrea ^{[12
]}

Burlando, Martina ^{[13
]}

Chiricozzi, Andrea ^{[14
,15
]}

Gaiani, Francesca Maria ^{[16
]}

Mugheddu, Cristina ^{[17
]}

Musumeci, Maria Letizia ^{[18
]}

Gisondi, Paolo ^{[19
]}

Piaserico, Stefano ^{[20
]}

Dapavo, Paolo ^{[21
]}

Venturini, Marina ^{[22
]}

Pagnanelli, Gianluca ^{[23
]}

Amerio, Paolo ^{[24
]}

Potenza, Concetta ^{[25
]}

Peris, Ketty ^{[14
,15
]}

Cantoresi, Franca ^{[26
]}

Trevisini, Sara ^{[27
]}

Loconsole, Francesco ^{[28
]}

Offidani, Annamaria ^{[29
]}

Mercuri, Santo Raffaele ^{[30
]}

Lora, Viviana ^{[31
]}

Prignano, Francesca ^{[32
]}

Bartezaghi, Marta ^{[33
]}

Oliva, Giovanni ^{[33
]}

Aloisi, Elisabetta ^{[33
]}

Orsenigo, Roberto ^{[33
]}

机构：

[1] IRCCS Humanitas Res Hosp, Unit Dermatol, Rozzano, Italy

[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[3] Univ Siena, S Maria alle Scotte Hosp, Dept Med Surg & Neurol Sci, Dermatol Sect, Siena, Italy

[4] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy

[5] Fdn Policlin Tor Vergata, Dermatol Unit, Rome, Italy

[6] Dept Med, Dermatol Sect, Perugia, Italy

[7] Univ Perugia, Perugia, Italy

[8] Azienda Osped Papardo, Unita Operat Complessa Dermatol, Messina, Italy

[9] St Antonio Abate Hosp, Unit Dermatol, Trapani, Italy

[10] Univ Perugia, Dept Med & Surg, Dermatol Clin Terni, Perugia, Italy

[11] San Pio Hosp, Dermatol Unit, Benevento, Italy

[12] Univ Modena & Reggio Emilia, Dept Dermatol, Modena, Italy

[13] Univ Genoa, DiSSal Sect Dermatol, Osped Policlin San Martino, Genoa, Italy

[14] Univ Cattolica Sacro Cuore, Ist Dermatol, Rome, Italy

[15] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

[16] IRCCS Policlin San Donato, Dermatol Unit, Milan, Italy

[17] Univ Cagliari, Dept Med Sci & Publ Hlth, Sect Dermatol, Cagliari, Italy

[18] Univ Catania, Dermatol Clin, Catania, Italy

[19] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy

[20] Univ Padua, Dept Med, Dermatol Unit, Padua, Italy

[21] Univ Turin, Dept Biomed Sci & Human Oncol, Dermatol Clin 2, Turin, Italy

[22] Univ Brescia ASST Spedali Civili, Dept Dermatol, Brescia, Italy

[23] Ist Dermopat Immacolata IDI IRCCS, Div Dermatol 1, Rome, Italy

[24] Univ G dAnnunzio, Dermatol Clin, Chieti, Italy

[25] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Dermatol Unit Daniele Innocenzi, Rome, Italy

[26] Univ Roma, Dept Med, Dermatol Unit, Rome, Italy

[27] Univ Trieste, Dept Dermatol, Trieste, Italy

[28] Univ Bari, Dept Dermatol, Bari, Italy

[29] Polytech Marche Univ, Dept Clin & Mol Sci, Dermatol Unit, Ancona, Italy

[30] Osped San Raffaele, Dermatol & Cosmetol Unit, Milan, Italy

[31] IRCCS, San Gallicano Dermatol Inst, Dept Clin Dermatol, Ctr Study & Treatment Psoriasis, Rome, Italy

[32] Univ Florence, Dept Hlth Sci, Dermatol Clin, Florence, Italy

[33] Novartis Farma SpA, Origgio, Italy

来源：

ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷

关键词：

interleukin-17A; psoriasis; PASI; 90; secukinumab; SEVERE PLAQUE PSORIASIS; WAIST CIRCUMFERENCE; WEIGHT CHANGE; DOUBLE-BLIND; OPEN-LABEL; EFFICACY; MULTICENTER; OBESITY; SAFETY; USTEKINUMAB;

D O I：

10.2340/00015555-3816

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.

引用

页数：7

共 41 条

[1]

[Anonymous], 2008, WAIST CIRCUMFERENCE

[2] Continued treatment with secukinumab is associated with high retention or regain of response [J].

Augustin, M. ;

Thaci, D. ;

Eyerich, K. ;

Pinter, A. ;

Radtke, M. ;

Lauffer, F. ;

Mrowietz, U. ;

Gerdes, S. ;

Pariser, D. ;

Lebwohl, M. ;

Sieder, C. ;

Melzer, N. ;

Reich, K. .

BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) :67-75

[3] Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis [J].

Baeten, Dominique ;

Sieper, Joachim ;

Braun, Juergen ;

Baraliakos, Xenofon ;

Dougados, Maxime ;

Emery, Paul ;

Deodhar, Atul ;

Porter, Brian ;

Martin, Ruvie ;

Andersson, Mats ;

Mpofu, Shephard ;

Richards, Hanno B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (26) :2534-2548

[4] Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab [J].

Bagel, J. ;

Tyring, S. ;

Rice, K. C. ;

Collier, D. H. ;

Kricorian, G. ;

Chung, J. ;

Iles, J. ;

Stolshek, B. S. ;

Kaliyaperumal, A. ;

Papp, K. A. .

BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (02) :411-418

[5]

Bagel J, 2018, J DRUGS DERMATOL, V17, P918

[6] Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5years of treatment (SCULPTURE Extension Study) [J].

Bissonnette, R. ;

Luger, T. ;

Thaci, D. ;

Toth, D. ;

Lacombe, A. ;

Xia, S. ;

Mazur, R. ;

Patekar, M. ;

Charef, P. ;

Milutinovic, M. ;

Leonardi, C. ;

Mrowietz, U. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) :1507-1514

[7] Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study [J].

Blauvelt, Andrew ;

Reich, Kristian ;

Tsai, Tsen-Fang ;

Tyring, Stephen ;

Vanaclocha, Francisco ;

Kingo, Kulli ;

Ziv, Michael ;

Pinter, Andreas ;

Vender, Ronald ;

Hugot, Sophie ;

You, Ruquan ;

Milutinovic, Marina ;

Thaci, Diamant .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (01) :60-+

[8] Redefining the therapeutic objective in psoriatic patients candidates for biological therapy [J].

Carretero, G. ;

Puig, L. ;

Carrascosa, J. M. ;

Ferrandiz, L. ;

Ruiz-Villaverde, R. ;

de la Cueva, P. ;

Belinchon, I. ;

Vilarrasa, E. ;

del Rio, R. ;

Sanchez-Carazo, J. L. ;

Lopez-Ferrer, A. ;

Peral, F. ;

Armesto, S. ;

Eiris, N. ;

Mitxelena, J. ;

Vilar-Alejo, J. ;

Martin, M. A. ;

Soria, C. .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (04) :334-346

[9] Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study [J].

Chiricozzi, Andrea ;

Balato, Anna ;

Conrad, Curdin ;

Conti, Andrea ;

Dapavo, Paolo ;

Ferreira, Paulo ;

Gaiani, Francesca Maria ;

Leite, Luiz ;

Malagoli, Piergiorgio ;

Mendes-Bastos, Pedro ;

Megna, Matteo ;

Messina, Francesco ;

Nidegger, Alessia ;

Odorici, Giulia ;

Panduri, Salvatore ;

Piaserico, Stefano ;

Piscitelli, Leonardo ;

Prignano, Francesca ;

Ribero, Simone ;

Valerio, Joana ;

Torres, Tiago .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (05) :476-483

[10]

Committee for medicinal products for human use, 2004, GUID CLIN INV MED PR

← 1 2 3 4 5 →